Zr89

DRUG3 trials

Sponsors

Amsterdam UMC, Universitair Medisch Centrum Groningen

Conditions

Breast cancerEsophageal CancerMelanomaNon-Small Cell Lung CarcinomaPatients with metastatic solid tumoursgiant cell arteritisrheumatoid arthritiswhere clinical data has shown a rationale for ICI therapy.

Phase 1

CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumors

RecruitingCTIS2024-515885-15-00

Universitair Medisch Centrum GroningenPatients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

Start: 2025-03-04Target: 16Updated: 2025-09-22

Phase 2

Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate)

RecruitingCTIS2023-509486-20-00

Amsterdam UMCBreast cancer, Esophageal Cancer, Melanoma +1

Start: 2024-05-29Target: 34Updated: 2025-01-30

CD8 T cell imaging by positron emission tomography with 89Zr-Df-crefmirlimab in giant cell arteritis and rheumatoid arthritis: a pilot study

RecruitingCTIS2024-514489-38-01

Universitair Medisch Centrum Groningengiant cell arteritis, rheumatoid arthritis

Start: 2024-11-26Target: 20Updated: 2025-07-08